Bayer Licenses Trius Antibiotic | Chemical & Engineering News
Volume 89 Issue 31 | p. 19 | Concentrates
Issue Date: August 1, 2011

Bayer Licenses Trius Antibiotic

Department: Business
Keywords: antibiotics, Bayer, Trius

Bayer Pharma will pay Trius Therapeutics $25 million up front for regional rights to torezolid, an antibiotic against gram-positive bacteria that is in Phase III trials to treat acute bacterial skin and skin structure infections (ABSSSI). The San Diego-based firm will allow Bayer to develop the antibiotic in Africa, Latin America, the Middle East, and Asia excluding North and South Korea. Bayer will pay 25% of the costs necessary to gain approval for torezolid as a treatment for ABSSSI and pneumonia, and potentially pay up to $69 million more in milestones.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment